Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Alessandro Dal Maso
Peripheral Blood Markers Identify Risk of Immune‐Related Toxicity in Advanced Non‐Small Cell Lung Cancer Treated With Immune‐Checkpoint Inhibitors
Oncologist
Cancer Research
Medicine
Oncology
Related publications
Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer
Cancer
Cancer Research
Oncology
Immune‐Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders With Advanced Non‐Small Cell Lung Cancer
Oncologist
Cancer Research
Medicine
Oncology
MA08.09 Impact of Brain Metastases in Immune Checkpoint Inhibitors (ICI) Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Treatment- And Immune-Related Adverse Events of Immune Checkpoint Inhibitors in Advanced Lung Cancer
Bioscience Reports
Biochemistry
Cell Biology
Molecular Biology
Biophysics
P1.01-63 Correlation Between Immune-Related Adverse Events and Efficacy of Immune-Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Immune Checkpoint Modulation for Non-Small Cell Lung Cancer
Clinical Cancer Research
Cancer Research
Oncology
P3.01-19 Sequencing of Ramucirumab+Docetaxel Post-Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer Patients
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Current Treatment Options in Oncology
Oncology
Pharmacology
Effect of Sex on the Efficacy of Patients Receiving Immune Checkpoint Inhibitors in Advanced Non‐small Cell Lung Cancer
Cancer Medicine
Cancer Research
Nuclear Medicine
Radiology
Imaging
Oncology
